Rentschler Biopharma

Are you looking for a CDMO partner for your advanced therapy programs? At Rentschler Biopharma, we offer comprehensive process and analytical development, and cGMP manufacturing services for viral vectors, along with project management and regulatory support.    Our customized viral vector solutions are designed to help you accelerate your cell and gene therapy programs from pre-clinical and clinical development to commercialization.   #RentschlerBiopharma #AdvancedTherapies #CGT #AAV #LVV #CDMO  

We are pleased to announce the launch of our new lentiviral vector (LVV) manufacturing toolbox at our dedicated advanced therapy site in Stevenage, UK. With increased research and positive clinical results across a wide range of therapeutic applications, LVVs are becoming increasingly prominent in the advanced therapy space. With this enhancement, we are now well positioned to serve the demand of therapeutic developers who utilize LVVs for gene modulation, including cell therapies, complementing our existing adeno-associated viral (AAV) vector services.    Christiane Bardroff, Chief Operating Officer at Rentschler Biopharma, commented: “Our 50-year legacy as a leading biopharmaceutical CDMO has been defined by our vision of advancing medicine to save lives, together. We made a strategic investment in the cell and gene therapy sector, starting with adeno-associated viral vector services, so we could offer our development and manufacturing expertise and sector experience to support innovators in this fast-developing space. We are now pleased to build on our success and augment this offering with lentiviral vectors. Our company remains dedicated to evolving our portfolio to enhance the health and quality of life for seriously ill patients around the world.”     Robert Panting, General Manager, Rentschler ATMP Ltd., added: “The new lentiviral vector manufacturing toolbox highlights our commitment to providing cutting-edge solutions that enable our clients to advance their viral vector programs from pre-clinical and clinical development to market. By integrating lentiviral vector process development and manufacturing to our services, we are better serving the market by meeting the growing needs of the evolving and vibrant global advanced therapies sector.”   #RentschlerBiopharma #CDMO #advancedtherapies #LVV #viralvectors 

We are looking forward to Advanced Therapies Europe in Lisbon next week. On September 11 at 11:45 am local time, Aled Charles, Director of Process Development, will give an insightful presentation on “Standardizing downstream processes to support success”, and elaborate on:    - How to develop a holistic approach to optimizing empty/full separation  - How to utilize mass photometry to support and accelerate process development  - How to generate a simple, transferable process for cGMP manufacturing    This session is a must attend for anyone looking to enhance their process development strategies. Learn more about our advanced therapy services: https://lnkd.in/eHuE5B9j   #ATE2024 #AdvancedTherapies #genetherapy #technicalexcellence   

Our Director Downstream Manufacturing, Serge M. Stamm, set out, in collaboration with scientists of XL-protein, (PhD) Michaela Gebauer, to develop a clonal and high-yield mammalian cell line for the manufacturing of a hyperactive human DNase I with extended plasma half-life. The results of this research have now been published in the 15th Anniversary edition of Pharmaceutics with the Special Issue “Improvement of Drug Bioavailability”.  Find out how, in order to expand the therapeutic utility of human DNase I, a variant of the enzyme was developed that has both a prolonged systemic half-life and a higher catalytic activity compared to Dornase alfa, the recombinant form of DNase I approved for inhaled therapy of cystic fibrosis.  The research is part of Rentschler Biopharma’s collaboration with XL-protein GmbH to manufacture a long-acting, hyperactive recombinant human deoxyribonuclease I (DNase I). Combining XL-protein’s proprietary PASylation® technology and Rentschler Biopharma’s expertise in bioprocess development, a process was developed with high yield for this modified DNase I which exhibits both strongly increased activity and an extended pharmacokinetic profile.     For more insights, please visit our website: https://lnkd.in/e4YiFmiH    #RentschlerBiopharma #CDMO  

Let’s talk! Our CEO Benedikt von Braunmühl and Tom Roberts, our President and General Manager, U.S. Operations, recently met with Pharma’s Almanac Editor in Chief David Alvaro, Ph.D. for an extensive conversation about our company history, our work with clients, our new state-of-the-art production line in Milford, MA, and the future of the CDMO industry. Want to find out more about how we are shaping the future of biomanufacturing? Then read the full interview here: https://lnkd.in/gz9SPcU7 #RenschlerBiopharma #ReliabilityYouCanTrust #CDMO

As an independent family-owned company, we live by the motto: Many hands, many minds, one team. Open, respectful cooperation characterizes our working environment at our international sites, where quality awareness, diligence and responsibility are our top priorities. Our commitment to patients with serious and rare diseases motivates us to give our best every day.  Learn more about what makes being part of our Milford team special by PJ Bouchard, Senior Director HR at our U.S. site:     “We believe our employees are at the center of our success. It is our intent to engage their hearts, their minds, and their hands. This philosophy drives our commitment to fostering an inclusive and dynamic work environment. Therefore, we aim to inspire and engage our employees, ensuring they feel valued and motivated every day. As leaders, we work to achieve this by creating and fostering a culture of trust and transparency where all employees are respected, inspired, and engaged.”    #RentschlerBiopharma #CDMO #ReliabilityYouCanTrust 

Are you attending Advanced Therapies Europe from September 10-12 in beautiful Portugal? Join us to explore our process development and cGMP manufacturing solutions for advanced therapies. Connect with Bertille Boudier to learn how we can support your gene therapy programs and drive success.    Mark your calendars for our technical talk on September 11, where Aled Charles, our Process Development Director, will discuss how to standardize downstream processes to support success.    Learn more about our advanced therapy capabilities and contact us here: https://lnkd.in/eHuE5B9j   #ATE2024 #AdvancedTherapies #genetherapy

Meet our exceptional U.S. Business Development Team driving innovation at Rentschler Biopharma, Jason Brady, Robin Lynge, Jenna Biedrzycki and Madhurima Saini, Ph.D. Together, we are committed to delivering unparalleled CDMO service solutions tailored to your needs. Jason Brady, our U.S. Business Development Lead, tells you more about what motivates this team every day:  “At Rentschler Biopharma, our clients and their patients are at the heart of everything we do. We are committed to strengthening client relationships both globally and in the U.S., while maintaining seamless collaboration with all Rentschler Biopharma sites. Our task is simple: to provide the biopharmaceutical industry with comprehensive bioprocess development and production solutions that drive new therapeutic options for patients worldwide. As we continue to grow, we are excited about the opportunities at our newly expanded, state-of-the-art U.S. facility in Milford, MA, and we look forward to partnering with you on your next project. Let’s build the future of biopharma together!” #RentschlerBiopharma #CDMO #ReliabilityYouCanTrust   

Exciting news for us and our valued clients in France: We are honored to announce that we have been officially recognized by the French Ministry of Research for our contribution to research and development.     This prestigious acknowledgement designates us as eligible for the Research Tax Credit (Crédit d'Impôt Recherche - CIR), a vital program that supports innovation and R&D activities of French Companies.    Dr. Susanne Gulden, Director Business Development and responsible for our clients in France, commented: “This recognition underscores our commitment to advancing solutions for rare and serious diseases. We’re excited to leverage our expertise in Analytical and Process Science in this context and to collaborate on many groundbreaking projects.”    This honor reflects our unwavering commitment to advancing technology and innovation, and we are eager to continue supporting your projects with our integrated service solutions.: https://lnkd.in/ecYrZ-Md    #RentschlerBiopharma #CDMO 

At Rentschler Biopharma, reliability you can trust is more than a promise – it's our commitment. Many years of experience and expertise in finding and manufacturing best-fit solutions, as well as certified quality management and advanced technologies, ensure our high-quality standards at our three sites. Brid Rooney, Vice President Quality Assurance and Quality Control about our quality standards of our Milford site:     "Our commitment to quality is evident in our reliability in biopharmaceutical manufacturing and delivery, successful inspection history, and experienced staff. We excel in producing and testing complex biopharmaceuticals, validated by the number of life-saving therapies worldwide that are supplied by us. Our advanced data governance and rigorous quality control systems ensure accurate, secure data and high-quality results. By focusing on state-of-the-art technologies and maintaining a culture of continuous learning, we support our clients and their patients.”    #RentschlerBiopharma #CDMO #ReliabilityYouCanTrust